S. Albelda
Immunology · 2001–2022
A researcher in the Science corpus: 11 papers; trusts 2 researchers and is trusted by 3 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 52 citations into it; #969 of 2,160 by trust here, #453 by citations
- Molecular Biology — 30 citations into it
- Cancer Research — 13 citations into it
Whom S. Albelda trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts S. Albelda overall
Papers from S. Albelda's perspective
Ordered by how strongly the researchers S. Albelda trusts endorse each paper. Same corpus, a different order for every researcher.
- Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis (Proceedings of the National Academy of Sciences of the United States of America)
- Subsets of Myeloid-Derived Suppressor Cells in Tumor Bearing Mice (Journal of Immunology)
- Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. (Blood)
- Coordinated regulation of myeloid cells by tumours (Nature reviews. Immunology)
- Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. (Cancer Cell)
- Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. (Trends in immunology)
- Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives (Immunological Reviews)
- The Yin‐Yang of tumor‐associated macrophages in neoplastic progression and immune surveillance (Immunological Reviews)
- Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer (Nature Reviews. Cancer)
- Use of Ly6G‐specific monoclonal antibody to deplete neutrophils in mice (Journal of Leukocyte Biology)
Their papers
- CAR T cells produced in vivo to treat cardiac injury (2022) — 1,136 citations
- Mesothelin-targeted CAR-T cell therapy for solid tumors (2020) — 124 citations
- Targeting Cardiac Fibrosis with Engineered T cells (2019) — 650 citations
- Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients (2016) — 687 citations
- Mesothelin-specific Chimeric Antigen Receptor mRNA-Engineered T cells Induce Anti-Tumor Activity in Solid Malignancies (2013) — 804 citations
- Tumor-associated neutrophils: friend or foe? (2012) — 708 citations
- Polarization of Tumor-Associated Neutrophil (TAN) Phenotype by TGF-β: “N1” versus “N2” TAN (2009) — 3,164 citations
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains (2009) — 871 citations
- Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity (2005) — 1,061 citations
- BRAF and RAS mutations in human lung cancer and melanoma. (2002) — 1,126 citations
- Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. (2001) — 641 citations